Eli Lilly and Company (NYSE:LLY) Price Target Raised to $865.00 at BMO Capital Markets

Eli Lilly and Company (NYSE:LLYFree Report) had its price objective lifted by BMO Capital Markets from $710.00 to $865.00 in a report published on Wednesday, Benzinga reports. BMO Capital Markets currently has an outperform rating on the stock.

LLY has been the subject of several other reports. Citigroup raised their price target on shares of Eli Lilly and Company from $525.00 to $675.00 and gave the stock a buy rating in a research note on Monday, October 23rd. TheStreet cut shares of Eli Lilly and Company from a b rating to a c+ rating in a research note on Monday, December 4th. JPMorgan Chase & Co. reaffirmed an overweight rating on shares of Eli Lilly and Company in a research note on Wednesday, November 8th. Morgan Stanley raised their price target on shares of Eli Lilly and Company from $727.00 to $822.00 and gave the stock an overweight rating in a research note on Tuesday, December 19th. Finally, Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an overweight rating in a research note on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $621.81.

View Our Latest Research Report on LLY

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $740.16 on Wednesday. The company has a market capitalization of $702.64 billion, a price-to-earnings ratio of 127.61, a P/E/G ratio of 2.10 and a beta of 0.32. The firm’s 50 day simple moving average is $620.02 and its 200 day simple moving average is $581.02. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.05 and a quick ratio of 0.82. Eli Lilly and Company has a fifty-two week low of $309.20 and a fifty-two week high of $745.70.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 50.78%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period last year, the company posted $2.09 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Thursday, February 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.70%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.13. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 77.93%.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 195,055 shares of company stock valued at $125,254,657. 0.13% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Buckhead Capital Management LLC boosted its holdings in Eli Lilly and Company by 0.7% in the fourth quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock worth $1,226,000 after acquiring an additional 15 shares in the last quarter. Levin Capital Strategies L.P. boosted its holdings in Eli Lilly and Company by 3.8% in the fourth quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock worth $242,000 after acquiring an additional 15 shares in the last quarter. Clearwater Capital Advisors LLC boosted its holdings in Eli Lilly and Company by 1.3% in the fourth quarter. Clearwater Capital Advisors LLC now owns 1,202 shares of the company’s stock worth $701,000 after acquiring an additional 15 shares in the last quarter. JGP Wealth Management LLC boosted its holdings in Eli Lilly and Company by 0.9% in the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after acquiring an additional 16 shares in the last quarter. Finally, Cassia Capital Partners LLC boosted its holdings in Eli Lilly and Company by 1.8% in the third quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock worth $511,000 after acquiring an additional 17 shares in the last quarter. Institutional investors own 81.38% of the company’s stock.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.